Crystallization (Comment) | Organism |
---|---|
structure of SARS-CoV-2 Mpro in complex with antimalarial drug tafenoquine. Tafenoquine noncovalently binds to and reshapes the substrate-binding pocket of Mpro by altering the loop region (residues 139-144) near the catalytic Cys145, which could block the catalysis of its peptide substrates | Severe acute respiratory syndrome coronavirus 2 |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
tafenoquine | 8-aminoquinoline antimalarial drug, directly inhibits SARS-CoV-2 Mpro in vitro. Tafenoquine binding reduces the helical content but also induces local conformational changes in SARS-CoV-2 Mpro, resulting in resistance to trypsin digestion. Tafenoquine inhibits SARS-CoV-2 production in a cell culture system | Severe acute respiratory syndrome coronavirus 2 |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Severe acute respiratory syndrome coronavirus 2 | - |
- |
- |
Synonyms | Comment | Organism |
---|---|---|
Mpro | - |
Severe acute respiratory syndrome coronavirus 2 |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.0318 | - |
pH 7.8, 25°C | Severe acute respiratory syndrome coronavirus 2 | tafenoquine |